Roflumilast cream 0.05% is being studied for mild to moderate AD in infants aged 3 months to under 2 years in a new phase 2 trial.
Mercedes E. Gonzalez, MD
Advertisement
Mercedes E. Gonzalez, MD, board-certified pediatric dermatologist, a clinical assistant professor at the FIU Herbert Wertheim School of Medicine and the Phillip Frost Department of Dermatology at the Miller School of Medicine; Medical Director at Pediatric Skin Research, Miami, Florida.
Articles by Mercedes E. Gonzalez, MD
Advertisement
Latest Updated Articles
Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitisPublished: June 27th 2025 | Updated:
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Transforming teen obesity care: How integrated specialty pharmacy models expand GLP-1 access
2
Redefining type 1 diabetes: Early identification, staging, and clinical implications for pediatric care
3
Daniele De Luca, MD, discusses zelpultide alfa in neonates at high risk of bronchopulmonary dysplasia development
4
CDC updates website, opens door for autism and vaccines link
5
